Marin Cancer Care

What Marin Cancer Care does

Marin Cancer Care (MCC) is a privately held, community oncology practice founded in 1978 and headquartered in Greenbrae, California (1350 South Eliseo Drive, Suite 200), serving adults with cancer and blood disorders across Marin and Sonoma counties. The practice operates three core clinical specialties — Medical Oncology (chemotherapy, immunotherapy, endocrine therapy, and targeted therapy), Radiation Oncology (two state-of-the-art linear accelerators including the Varian TrueBeam, with a GE LightSpeed RT CT simulator supporting IGRT, IMRT, SBRT, and SRS), and Hematology — under a single roof, supplemented by an on-site Phase I–III Clinical Trials Program with sponsors including Eli Lilly, BMS, Roche/Genentech, Janssen, Natera, Exact Sciences, PDS Biotech, and NRG Oncology, and an Integrative Wellness Program (acupuncture, massage, mindfulness, Qigong, nutrition, lymphedema education, Horses as Healers, and Zoom meditation) delivered in partnership with MarinHealth (a UCSF affiliate) and community organizations.

The clinical platform is staffed by 6 medical oncologists and 4 radiation oncologists with credentials from Harvard, Stanford, UCSF, UCLA, UC San Diego, Georgetown, Duke, Columbia, Tulane, Johns Hopkins, and Fox Chase, alongside oncology-certified nurses, specialized breast and genitourinary patient navigators, clinical care coordinators, an in-house pharmacist, a research coordinator, a director of nursing, a practice manager, and CEO Joel Criste. The job posting advertises a physician "ownership track" in the practice and its infusion center, indicating a physician-ownership model rather than external capital ownership.

Revenue mechanics are fee-for-service professional billing through patient insurance for consultations, chemotherapy infusion, radiation therapy, hematology workups, and procedures, supplemented by per-patient payments from sponsored clinical trial participation and downstream ancillary services (DigniCap cold cap therapy, integrative wellness). Customer acquisition is predominantly direct-to-consumer and physician-referral based, supported by a content-marketing blog (Marin Cancer News), free community classes, peer-recognition awards (Marin Magazine {415} Top Doctors; Pacific Sun Best of Marin), and tight clinical integration with MarinHealth/UCSF. No external funding rounds, ticker, SEC filings, or M&A activity are disclosed; a cybersecurity incident (unauthorized network access between November 22 and December 6, 2025; public notice updated February 6, 2026) has been disclosed and is under third-party investigation.

Name

Marin Cancer Care

Legal name

Marin Cancer Care

Website

https://marincancercare.com

Company type

Private

Founded year

1978

Operating status

Operating

Headcount range

11–50 employees

Short description

Marin Cancer Care is a privately held, community oncology practice founded in 1978 in Greenbrae, California, delivering integrated medical oncology, radiation oncology, hematology, Phase I–III clinical trials, and integrative wellness to cancer patients in Marin and Sonoma counties.

Ownership category

akta.pro rank

Product category

Community Oncology Services

NAICS

Offices of Physicians (62111), Diagnostic Imaging Centers (621512)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Hospitals (8060), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Radiation Oncology (HLAKAFAC)

Keywords

• Community oncology services
• Cancer treatment center
• Radiation oncology therapy
• Clinical trials oncology
• Integrative wellness programs

Headquarters

HQ city

Greenbrae

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Cancer Treatment Services (Medical & Radiation Oncology, Hematology): Fee-for-service medical care including office consultations, chemotherapy infusion, radiation therapy treatments, hematology treatments, and procedures. Billing typically through patient insurance. The job posting notes a '1:7 call schedule' for medical oncologists, indicating professional services revenue.
2. Clinical Trials Research Services: Revenue from sponsored clinical trial participation across Phase 1–3 studies with multiple pharmaceutical/biotech sponsors (e.g., Eli Lilly, BMS, Exact Sciences, Natera). Managed by a dedicated Research Coordinator.
3. Integrative Wellness & Support Services: Free support groups and classes offered through Marin General Hospital Center for Integrative Health & Wellness (acupuncture, massage, mindfulness, nutrition, Qigong, Horses as Healers, lymphedema education). Listed as complimentary/charitable services rather than revenue, but ancillary oncology-support services can drive downstream clinical revenue.
4. Infusion Center Services: Ownership opportunity in the practice's infusion center mentioned in the oncologist job posting, indicating revenue from in-house infusion services and chemotherapy administration.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Marin Cancer Care is a private, community oncology practice that delivers integrated cancer care through three core clinical specialties — medical oncology (chemotherapy, immunotherapy, endocrine, targeted therapy), radiation oncology (IGRT, IMRT, SBRT, SRS via Varian TrueBeam and GE LightSpeed RT CT), and hematology — supported by an on-site Phase I–III clinical trials program, DigniCap scalp cooling, and an integrative wellness program (acupuncture, massage, mindfulness, nutrition, Qigong). The practice provides patient navigation, infusion services, and care coordination aligned with MarinHealth (a UCSF affiliate) for surgical, imaging, genetic counseling, dietary, and psychosocial support.

Product overview

Marin Cancer Care (MCC) operates as a single integrated community oncology practice, founded in 1978 and located in Greenbrae, CA, that delivers a unified cancer care platform combining three core clinical specialties — Medical Oncology, Radiation Oncology, and Hematology — under one roof. These clinical pillars are supplemented by an on-site Clinical Trials Program (Phase I–III across breast, prostate, lung, GU, head & neck, and supportive care) and an Integrative Wellness Program offering acupuncture, massage, mindfulness/meditation, Qigong, nutrition, and lymphedema education. Patient Navigation Service coordinates care across facilities, while DigniCap Cold Cap Therapy and the Varian TrueBeam and GE LightSpeed RT CT Simulator provide supportive and radiation-oncology technology. MCC is aligned with MarinHealth (a UCSF affiliate) for surgical, imaging, navigation, genetic counseling, dietary, and psychosocial support access. The practice serves Marin and Sonoma County and operates one Greenbrae office at 1350 South Eliseo Drive, Suite 200.

Differentiator

Problem solved

Functional benefit

Products and services

• Medical Oncology Diagnosis and treatment of cancer using systemic medications including chemotherapy, immunotherapy, endocrine therapy, and targeted therapy (oral, intravenous, and injectable), customized using biochemistry, molecular studies, and genetic studies and combined with surgery and radiation where appropriate. Provided to adult cancer patients in Marin and Sonoma counties.
• Radiation Oncology Targeted radiation therapy delivered via two state-of-the-art linear accelerators (including Varian TrueBeam) and a GE LightSpeed RT CT simulator, offering IGRT, IMRT, SBRT, and SRS modalities for adult cancer patients in Marin and Sonoma counties.
• Hematology Diagnosis and treatment of blood disorders (both benign and malignant), including anemia, blood clots, leukemia, and lymphoma, through blood tests and bone marrow biopsies. Provided to patients with benign or malignant hematologic conditions, including those without a cancer diagnosis.
• Clinical Trials Program On-site Phase I, II, and III oncology clinical trials covering breast, prostate, rare genitourinary, head and neck, lung cancers, and hematologic/supportive care studies (e.g., Giredestrant, COPERNICUS, KRASCENDO, ICONIC, BESPOKE/Natera MRD, PT2PC psilocybin trial). Overseen by Dr. Cyrus Mazidi, with a dedicated Research Coordinator. Available to eligible oncology patients.
• Integrative Wellness Program Holistic support services including acupuncture, massage, mindfulness/meditation training, nutrition guidance, Qigong classes (Beginner, Experienced, Everyone), Monthly Zoom Meditations, Horses as Healers equine therapy, Lymphedema Education Series, and Nutrition for Cancer Survivors Brunch & Learn series. Provided to cancer patients, survivors, caregivers, and family members.
• Patient Navigation Service Care coordination and patient navigation services with specialized breast and genitourinary navigators who coordinate care across facilities, take notes during appointments, and connect patients with resources. Provided to oncology patients at Marin Cancer Care.
• Cold Cap Therapy (DigniCap) Supportive care offering using the DigniCap Scalp Cooling System (FDA-cleared, December 2015) and Penguin cold caps chilled to -30°C to -32°C to reduce chemotherapy-induced hair loss. Provided to eligible chemotherapy patients, with Pink Aid grants supporting breast cancer patients.

Quantifiable outcome

• Dr. Bobbie Head involved in 100+ clinical trials
• +3 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature8 records

Partnerships

25 partnerships are on record, tiered flagship, minor and core.

• MarinHealth (UCSF Affiliate)flagshipStrategic or Co-development PartnerMarin Cancer Care is aligned with MarinHealth, a UCSF affiliate facility. The cancer center provides access to MarinHealth's surgical colleagues, state-of-the-art imaging, nurse navigation, genetic counseling, dietary, and psychosocial support. MarinHealth also hosts, sponsors and facilitates free support groups and is co-branded on virtual wellness classes (e.g., Monthly Zoom Meditations, Qigong, Horses as Healers, Brunch & Learn).
• Mayo ClinicminorStrategic or Co-development PartnerMarin Cancer Care physicians collaborate with the Mayo Clinic on clinical research; the Mayo Clinic 'regularly calls on MCC for insights on the latest clinical research and innovations in patient care.'
• National Cancer Institute (NCI)minorStrategic or Co-development PartnerThe National Cancer Institute 'regularly calls on MCC for insights on the latest clinical research and innovations in patient care.' NCCN also mentioned in Dr. Poen's professional affiliations.
• American Society of Clinical Oncology (ASCO)minorStrategic or Co-development PartnerASCO 'regularly calls on MCC for insights on the latest clinical research and innovations in patient care.' Multiple MCC physicians (Dr. Anderson, Dr. Galligan, etc.) hold ASCO professional society memberships.
• Varian (TrueBeam Linear Accelerator)coreTechnology or IntegrationMCC operates two state-of-the-art linear accelerators including the Varian TrueBeam system, the world's first image-guided radiation therapy system optimized for both conventional and stereotactic approaches to treating cancer.
• GE (LightSpeed RT CT Simulator)coreTechnology or IntegrationMCC uses the GE LightSpeed RT CT simulator which produces high-resolution images for precise tumor marking; described as the first multi-slice CT scanner dedicated to radiation therapy.
• Dignitana (DigniCap Scalp Cooling System)coreTechnology or IntegrationMCC offers the DigniCap Scalp Cooling System to help patients reduce hair loss during chemotherapy. Dignitana received FDA clearance for the system in December 2015.
• NRG Oncology (NRG-GU008 INNOVATE trial)coreStrategic or Co-development PartnerSponsor of the INNOVATE trial — a Phase III randomized trial incorporating apalutamide and advanced imaging into salvage treatment for patients with node positive prostate cancer after radical prostatectomy.
• Eli LillycoreStrategic or Co-development PartnerSponsor of multiple clinical trials at MCC including J2R-MC-YAAD (Phase 2 study of LY3537021 for chemotherapy-induced nausea and vomiting) and PIKALO-2 / J6M-MC-JSGD (Phase 3 Giredestrant in HR+/HER2- advanced breast cancer with PIK3CA mutation).
• Bristol-Myers Squibb (BMS)coreStrategic or Co-development PartnerSponsor of the CA2430001 Phase 1 first-in-human study of BMS-986500 as monotherapy in advanced solid tumors and combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.
• Roche / Genentech (CO44657 Giredestrant)coreStrategic or Co-development PartnerSponsor of the CO44657 Phase III randomized open-label study evaluating efficacy and safety of Giredestrant compared with Fulvestrant, both combined with a CDK4/6 inhibitor, in ER+/HER2- advanced breast cancer patients with resistance to prior adjuvant endocrine therapy.
• Janssen (COPERNICUS)coreStrategic or Co-development PartnerSponsor of the COPERNICUS Phase 2 study of subcutaneous Amivantamab in combination with Lazertinib as first-line treatment for common EGFR-mutated locally advanced or metastatic NSCLC.
• Exact SciencescoreStrategic or Co-development PartnerSpecimen collection partner for study 2021-05 evaluating biomarkers in whole blood and tumor tissue specimens from subjects with cancer or recurrent cancer.
• Natera (BESPOKE study)coreStrategic or Co-development PartnerBESPOKE prospective multi-center single-arm study designed to collect data to clinically characterize biomarkers associated with Natera test(s) (Signatera, Signatera Genome, Latitude) from participants diagnosed with Stage I to IV tumors.
• PDS Biotech (VERSATILE-3)coreStrategic or Co-development PartnerSponsor of the VERSATILE-3 Phase III study of PDS0101 plus Pembrolizumab vs Pembrolizumab alone in first-line treatment of ICI-naïve subjects with unresectable R/M HPV16-positive HNSCC (currently on hold).
• Genentech / Roche (KRASCENDO)coreStrategic or Co-development PartnerSponsor of the KRASCENDO Phase III study evaluating efficacy and safety of Divarasib and Pembrolizumab vs Pembrolizumab and Pemetrexed/Carboplatin or Cisplatin in KRAS G12C-Mutated NSCLC.
• SMC Marin (Stress Management Center) / Rich DanoncoreImplementation/ SI/ Consulting PartnerProvides free Qigong classes (Experienced, Everyone, Beginner Practice) at the Marin Cancer Care office. Instructor Rich Danon is a Certified Yuan Qigong Teacher; registration via www.smcmarin.com/stress-management-center-schedule.
• Miwok Equestrian CentercoreImplementation/ SI/ Consulting PartnerHosts the 'Horses as Healers' program for cancer patients on Tuesdays 11:00 AM–1:00 PM; medical clearance required.
• MarinHealth (Wellness/Classes Co-branding)coreGTM or Marketing PartnerMarinHealth co-brands virtual wellness classes and provides Lymphedema Education Series instructor (Jenn Fernandez, PTA, Certified Lymphedema and Oncology Rehabilitation Therapist); co-promotes Brunch & Learn Series.
• Marin MagazineminorGTM or Marketing PartnerPublishes the {415} Top Doctors list on which all Marin Cancer Care physicians appear. Methodology: peer-to-peer voting poll across 3,600+ licensed doctors in San Francisco and Marin counties; rechecked annually.
• American Cancer SocietyminorGTM or Marketing PartnerListed as an Online Support Resource on Marin Cancer Care's Integrative Wellness page for patient referrals.
• Susan G. Komen FoundationminorGTM or Marketing PartnerListed as a patient support resource on the Marin Cancer Care Integrative Wellness page.
• NeedyMedsminorGTM or Marketing PartnerListed as a financial assistance resource for patients on the Marin Cancer Care Integrative Wellness page.
• Patient Advocate FoundationminorGTM or Marketing PartnerListed as a financial/legal assistance resource on the Marin Cancer Care Integrative Wellness page.
• Ceres Community Project Marin/SonomaminorGTM or Marketing PartnerMeals prepared by local teens with chef mentors and delivered to families dealing with serious illness — listed as a patient resource.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Tennessee Oncology: Large private community oncology practice offering medical oncology, radiation oncology, hematology, and clinical trials across multiple Tennessee sites — directly comparable business model (physician-owned, community-based, integrated research) to Marin Cancer Care, but at much greater scale.
• Florida Cancer Specialists & Research Institute: One of the largest independent community oncology practices in the U.S., with an extensive Phase I–III clinical trials program. Operates the same integrated medical/radiation oncology + clinical research model as Marin Cancer Care, at significantly greater geographic scale.
• Virginia Cancer Specialists: Private community oncology practice providing medical oncology, hematology, radiation oncology, and clinical research across Northern Virginia. Closely mirrors MCC's 'whole person' community-based model with embedded clinical trials.
• New York Cancer & Blood Specialists: Independent community oncology and hematology practice with a robust in-house clinical trials program across the New York metro area. Directly comparable integrated specialty + research model to Marin Cancer Care.
• Northwest Medical Specialties: Private community oncology practice in the Pacific Northwest offering medical oncology, hematology, infusion, and clinical trials — comparable integrated community-oncology + research model to Marin Cancer Care, though with different geographic catchment.

Broad incumbents

• OneOncology: National platform for independent community oncology practices providing practice management, capital, technology, and group purchasing. MCC could be a candidate partner or comparable independent community practice evaluating OneOncology affiliation.
• The US Oncology Network (McKesson): Large network of independent community oncology practices supported by McKesson, offering practice management, payer contracting, drug distribution, and clinical research services. A competitor / potential affiliation option for MCC's clinical trials program.
• City of Hope (formerly Cancer Treatment Centers of America): National cancer care system providing medical oncology, radiation oncology, hematology, and clinical trials across multiple sites; now affiliated with City of Hope. Represents a larger, multi-state incumbent operating in the same oncology service categories as MCC.
• UCSF Helen Diller Family Comprehensive Cancer Center: NCI-designated academic comprehensive cancer center; MarinHealth (MCC's primary hospital partner) is a UCSF affiliate. Represents both a clinical partner and a potential competitive referral sink for complex oncology cases in the Bay Area.
• Stanford Cancer Institute: NCI-designated academic cancer center serving the greater Bay Area, including patients who might otherwise seek community oncology care. Represents a competitive threat via satellite expansion, telehealth, and clinical trial access that could erode MCC's catchment area.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marin Cancer Care